Forkhead box protein p 1 is a transcriptional repressor of immune signaling in the CNS : implications for transcriptional dysregulation in Huntington disease

Forkhead box protein p1 (Foxp1), a transcription factor showing highly enriched expression in the striatum, has been implicated in central nervous system (CNS) development, but its role in the mature brain is unknown. In order to ascertain functional roles for Foxp1 in the CNS, we have identified gene targets for Foxp1 both in vitro and in vivo using genome-wide expression microarrays and chromatin-immunoprecipitation followed by high-throughput sequencing (ChIP-seq) assays. We found that mouse Foxp1 overexpression in striatal cells elicited expression changes of genes related to immune signaling, transcriptional regulation and a manually curated Huntington's disease (HD)-signaling pathway. Similar results were found when the gene expression data set was integrated with Foxp1-binding data determined from ChIP-seq analysis. In vivo lentiviral-mediated overexpression of human FOXP1 in the context of mutant huntingtin (Htt) protein resulted in a robust downregulation of glial cell-associated, immune genes, including those encoding a variety of cytokines and chemokines. Furthermore, Foxp1-induced expression changes were significantly negatively correlated with those changes elicited by mutant Htt protein in several different HD mouse models, and most significantly in post-mortem caudate from human HD subjects. We finally show that Foxp1 interacts with mutant Htt protein in mouse brain and is present in nuclear Htt aggregates in the striatum of R6/1 transgenic mice. These findings implicate Foxp1 as a key repressor of immune signaling in the CNS and suggest that the loss of Foxp1-mediated gene regulation in HD contributes to the immune dysfunction in this disease. We further suggest that Foxp1-regulated pathways might be important mediators of neuronal-glial cell communication.

[1]  D. Dickson,et al.  Expanded-Polyglutamine Huntingtin Protein Suppresses the Secretion and Production of a Chemokine (CCL5/RANTES) by Astrocytes , 2008, The Journal of Neuroscience.

[2]  Chuan-en Wang,et al.  Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms , 2009, Proceedings of the National Academy of Sciences.

[3]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[4]  M. Mattson,et al.  NF-kappaB in neuronal plasticity and neurodegenerative disorders. , 2001, The Journal of clinical investigation.

[5]  K. Asadullah,et al.  Interleukin-10 Therapy—Review of a New Approach , 2003, Pharmacological Reviews.

[6]  S. Ziegler,et al.  Scurfin (FOXP3) Acts as a Repressor of Transcription and Regulates T Cell Activation* , 2001, The Journal of Biological Chemistry.

[7]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[8]  A. Hamby,et al.  Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[9]  A. Monaco,et al.  Identification of FOXP1 Deletions in Three Unrelated Patients with Mental Retardation and Significant Speech and Language Deficits , 2010, Human mutation.

[10]  C Fidler,et al.  The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. , 2001, Cancer research.

[11]  D. Kleinjan,et al.  Long-range control of gene expression: emerging mechanisms and disruption in disease. , 2005, American journal of human genetics.

[12]  E. Thomas,et al.  Functional roles for the striatal-enriched transcription factor, Bcl11b, in the control of striatal gene expression and transcriptional dysregulation in Huntington's disease , 2008, Neurobiology of Disease.

[13]  Kaoru Takahashi,et al.  Expression of Foxp2, a gene involved in speech and language, in the developing and adult striatum , 2003, Journal of neuroscience research.

[14]  S. Mémet,et al.  NF-κB functions in the nervous system: From development to disease , 2006 .

[15]  T. van der Poll,et al.  Proinflammatory Effects of IL-10 During Human Endotoxemia1 , 2000, The Journal of Immunology.

[16]  D. Geschwind,et al.  In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons. , 2011, Human molecular genetics.

[17]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[18]  M. Greene,et al.  FOXP3 Actively Represses Transcription by Recruiting the HAT/HDAC Complex , 2007, Cell cycle.

[19]  Coordinated Actions of the Forkhead Protein Foxp1 and Hox Proteins in the Columnar Organization of Spinal Motor Neurons , 2008, Neuron.

[20]  T. Prolla,et al.  Evolution of the Aging Brain Transcriptome and Synaptic Regulation , 2008, PloS one.

[21]  L. Staudt,et al.  Decision making in the immune system: Lymphoid Malignancies: the dark side of B-cell differentiation , 2002, Nature Reviews Immunology.

[22]  J. Buhler,et al.  Quantitative assessment of transcriptome differences between brain territories. , 2003, Genome research.

[23]  Y. Xing,et al.  A Transcriptome Database for Astrocytes, Neurons, and Oligodendrocytes: A New Resource for Understanding Brain Development and Function , 2008, The Journal of Neuroscience.

[24]  Mauro Delorenzi,et al.  Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. , 2007, Human molecular genetics.

[25]  K. Davies,et al.  Functional genetic analysis of mutations implicated in a human speech and language disorder. , 2006, Human molecular genetics.

[26]  P G Bhide,et al.  Early and Progressive Accumulation of Reactive Microglia in the Huntington Disease Brain , 2001, Journal of neuropathology and experimental neurology.

[27]  Ji-Yeon Shin,et al.  Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity , 2005, The Journal of cell biology.

[28]  T. Chatila,et al.  FOXP3 is a homo-oligomer and a component of a supramolecular regulatory complex disabled in the human XLAAD/IPEX autoimmune disease. , 2007, International immunology.

[29]  I. Verma,et al.  Design and cloning of lentiviral vectors expressing small interfering RNAs , 2006, Nature Protocols.

[30]  T. Jessell,et al.  Hox Repertoires for Motor Neuron Diversity and Connectivity Gated by a Single Accessory Factor, FoxP1 , 2008, Cell.

[31]  P. Patterson,et al.  Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[32]  D. Geschwind,et al.  Gene expression profiling of R6/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntington's disease , 2011, Neurobiology of Disease.

[33]  S. Barger,et al.  S100B‐induced microglial and neuronal IL‐1 expression is mediated by cell type‐specific transcription factors , 2005, Journal of neurochemistry.

[34]  Bin Wang,et al.  Foxp1 regulates cardiac outflow tract, endocardial cushion morphogenesis and myocyte proliferation and maturation , 2004, Development.

[35]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[36]  S. Tabrizi,et al.  Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. , 2007, Journal of proteome research.

[37]  G. Bing,et al.  Glial cell line-derived neurotrophic factor protects midbrain dopaminergic neurons against lipopolysaccharide neurotoxicity , 2010, Journal of Neuroimmunology.

[38]  C. Röpke,et al.  Suppressors of cytokine signalling: SOCS , 2002, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[39]  A. Monaco,et al.  A forkhead-domain gene is mutated in a severe speech and language disorder , 2001, Nature.

[40]  Brian C. Jackson,et al.  Update of human and mouse forkhead box (FOX) gene families , 2010, Human Genomics.

[41]  Maria Jansson,et al.  Targeted transgene expression in rat brain using lentiviral vectors , 2003, Journal of neuroscience research.

[42]  H. Boddeke,et al.  Neuronal Chemokines: Versatile Messengers In Central Nervous System Cell Interaction , 2007, Molecular Neurobiology.

[43]  J. Olson,et al.  Regional and cellular gene expression changes in human Huntington's disease brain. , 2006, Human molecular genetics.

[44]  S. Rogers,et al.  Neuronal expression of tumor necrosis factor alpha in the murine brain. , 1996, Neuroimmunomodulation.

[45]  D. Dean,et al.  Rb Interacts with Histone Deacetylase to Repress Transcription , 1998, Cell.

[46]  P. Carlsson,et al.  Forkhead transcription factors: key players in development and metabolism. , 2002, Developmental biology.

[47]  M. Hayden,et al.  Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis. , 2010, Human molecular genetics.

[48]  Claire-Anne Gutekunst,et al.  A YAC Mouse Model for Huntington’s Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration , 1999, Neuron.

[49]  S. Rutz,et al.  Regulation and functions of the IL-10 family of cytokines in inflammation and disease. , 2011, Annual review of immunology.

[50]  N. Sykes,et al.  Identification of FOXP2 truncation as a novel cause of developmental speech and language deficits. , 2005, American journal of human genetics.

[51]  J. Nardone,et al.  Foxp1 is an essential transcriptional regulator of B cell development , 2006, Nature Immunology.

[52]  M. Hayden,et al.  A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease , 2008, The Journal of experimental medicine.

[53]  P. Patterson,et al.  Activation of the IκB Kinase Complex and Nuclear Factor-κB Contributes to Mutant Huntingtin Neurotoxicity , 2004, The Journal of Neuroscience.

[54]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[55]  Christopher A Walsh,et al.  Characterization of Foxp2 and Foxp1 mRNA and protein in the developing and mature brain , 2003, The Journal of comparative neurology.

[56]  E. Fombonne,et al.  De novo mutations in FOXP1 in cases with intellectual disability, autism, and language impairment. , 2010, American journal of human genetics.

[57]  D J Brooks,et al.  Microglial activation correlates with severity in Huntington disease , 2006, Neurology.

[58]  C. Ballantyne,et al.  Integrin engagement regulates monocyte differentiation through the forkhead transcription factor Foxp1. , 2004, The Journal of clinical investigation.

[59]  D. Rubinsztein,et al.  Transcriptional abnormalities in Huntington disease. , 2003, Trends in genetics : TIG.

[60]  S. Mémet NF-kappaB functions in the nervous system: from development to disease. , 2006, Biochemical pharmacology.

[61]  Weiguo Shu,et al.  Characterization of a New Subfamily of Winged-helix/Forkhead (Fox) Genes That Are Expressed in the Lung and Act as Transcriptional Repressors* , 2001, The Journal of Biological Chemistry.

[62]  E. Thomas,et al.  Striatal specificity of gene expression dysregulation in Huntington's disease , 2006, Journal of neuroscience research.

[63]  Yen F. Tai,et al.  Imaging microglial activation in Huntington's disease , 2007, Brain Research Bulletin.

[64]  M. MacDonald,et al.  Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. , 2000, Human molecular genetics.

[65]  Hwan-Suck Chung,et al.  Foxp3 is a novel repressor of microglia activation , 2010, Glia.

[66]  J. Sutcliffe,et al.  Selective deficits in the expression of striatal‐enriched mRNAs in Huntington's disease , 2006, Journal of neurochemistry.

[67]  W. Alexander,et al.  The suppressors of cytokine signalling (SOCS) , 2001, Cellular and Molecular Life Sciences CMLS.

[68]  E. Masliah,et al.  Beclin 1 Gene Transfer Activates Autophagy and Ameliorates the Neurodegenerative Pathology in α-Synuclein Models of Parkinson's and Lewy Body Diseases , 2009, The Journal of Neuroscience.

[69]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[70]  P. Musiani,et al.  IL‐6 Expression in Neurons of Transgenic Mice Causes Reactive Astrocytosis and Increase in Ramified Microglial Cells but no Neuronal Damage , 1995, The European journal of neuroscience.

[71]  Alexander Gerhard,et al.  Microglial activation in presymptomatic Huntington's disease gene carriers. , 2005, Brain : a journal of neurology.

[72]  G. Ippolito,et al.  Foxp1 is an essential transcriptional regulator for the generation of quiescent naive T cells during thymocyte development. , 2010, Blood.

[73]  Mark P. Mattson,et al.  NF-κB in neuronal plasticity and neurodegenerative disorders , 2001 .

[74]  E. Morrisey,et al.  Coordinated Actions of the Forkhead Protein Foxp1 and Hox Proteins in the Columnar Organization of Spinal Motor Neurons , 2008, Neuron.

[75]  E. Senba,et al.  Expression pattern of the winged-helix/forkhead transcription factor Foxp1 in the developing central nervous system. , 2003, Gene expression patterns : GEP.